Health
Dapagliflozin Misses Early Mark in COVID-19, but Kosiborod Sees Reasons for More Study – AJMC.com Managed Markets Network
The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective…
A study that misses its mark would not typically generate this much interest, especially after trial sponsor AstraZeneca announced last month that results fell short of statistical significance. But with SGTL2 inhibitors gaining indications in heart failure and CKD, along with their original T2D approvalsconditions that put patients in danger when they get COVID-19many suspect this weekends results will not be the last word.
Since Kosiborod is one of the worlds leading experts on SGLT2 inhibitors,…
-
General21 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
General15 hours agoAshes engulfed by fresh DRS controversy as TV umpire gives Jamie Smith out despite RTS ‘murmur’
-
Noosa News19 hours agoMeticulously crafted home in heart of Noosa Heads
-
General18 hours ago‘Mother’s Day’ solar storm squeezed Earth’s plasmasphere to one-fifth its size